Clinical trials: Pneumopathy
Infection, Cross Infection
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after…
- Conditions
- Infection, Cross Infection, Bacterial Infections, Pneumonia, Ventilator-Associated
- Trial name
- NCT00965848
- Testing
- Doripenem
- Where
- 8 sites in Thailand
- Volunteers
- 270 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
Recurrent Small-cell Lung Cancer (SCLC), Lung Cancer, Small Cell
Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will increase delivery of topotecan to tumor cells…
- Trial name
- NCT00698516
- Testing
- Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
- Where
- 16 sites in United States
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with carboplatin and paclitaxel, and to assess the pharmacokinetics of CS-7017 in…
- Trial name
- NCT01199055
- Testing
- CS-7017, Carboplatin, Paclitaxel
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Asthma
Asthma Intervention Research (AIR) Trial
The purpose of this study is to demonstrate the effectiveness and safety of the Alair System for the treatment of asthma. This will be a multicenter, randomized controlled study comparing the effects of treatment with the Alair…
- Trial name
- NCT00214526
- Testing
- Bronchial thermoplasty with the Alair System, Conventional therapy with ICS+LABA
- Volunteers
- 112 people
- Sponsor
- Asthmatx, Inc.
Non-Small Cell Lung Cancer
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with…
- Trial name
- NCT00257608
- Testing
- bevacizumab, erlotinib HCl
- Where
- 247 sites in United States, Argentina and 15 more
- Volunteers
- 1,145 people
- Sponsor
- Genentech, Inc.
SARS-CoV-2 Infection, COVID-19
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
Substudy A: The study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to participants having previously received 2 doses of BNT162b2 at least 6 months prior to randomization.
- Trial name
- NCT04955626
- Testing
- BNT162b2, BNT162b2 OMI, Combination BNT162b2 and BNT162b2 OMI
- Where
- 154 sites in United States, Brazil and 3 more
- Volunteers
- 16,372 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Pulmonary Disease, Chronic Obstructive
Tiotropium Respimat Pharmacokinetic Study in COPD
The purpose of this study is compare the effect of different doses of tiotropium delivered by the HandiHaler and Respimat device on lung function.
- Trial name
- NCT01222533
- Testing
- Tiotropium medium, Tiotropium low, Tiotropium high
- Where
- 11 sites in Belgium, Denmark and 3 more
- Volunteers
- 154 people
- Sponsor
- Boehringer Ingelheim
Asthma
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.
- Trial name
- BAI (NCT01360021)
- Testing
- Symbicort, Budesonide
- Where
- 41 sites in United States, Bulgaria and 2 more
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)
This is a Phase II, double-blind, randomized, multicenter trial designed to preliminarily evaluate the activity and safety of treatment with MetMAb + erlotinib versus erlotinib + placebo in second- and third-line Non-Small Cell…
- Trial name
- NCT00854308
- Testing
- Erlotinib HCl, MetMAb
- Volunteers
- 137 people
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time.
- Trial name
- NCT06317285
- Testing
- GSK3915393
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Covid19
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
This is a 2-part, 2-arm, Phase 2 , multicentre, randomized, double-blind, placebo-controlled study in adults with COVID-19 with gastrointestinal infection.
- Trial name
- RESERVOIR (NCT04858425)
- Testing
- Niclosamide
- Where
- 25 sites in United States, India and 1 more
- Volunteers
- 166 people
- Sponsor
- Entero Therapeutics
Cystic Fibrosis
PTC Study to Evaluate Ataluren in Combination With Ivacaftor
The purpose of this study is to explore the combination of ataluren and ivacaftor as a treatment for patients with nonsense mutation cystic fibrosis
- Trial name
- NCT03256968
- Testing
- Ataluren
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Alabama at Birmingham
Covid19
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and…
- Trial name
- NCT04732468
- Testing
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Chronic Obstructive Pulmonary Disease
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
This study compared the efficacy of indacaterol versus placebo in COPD patients classified as GOLD 2014 Patient Group B. This was a 2-arm parallel group study that recruited COPD patients classified by GOLD Patient Gorup B.
- Trial name
- NCT02418468
- Testing
- Indacaterol
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Cystic Fibrosis
Electro Flo 5000 and Vest Therapy
It is the goal of the proposed study to compare the efficacy, as assessed primarily by sputum weight, of these two different devices (the Electroflo 500 and VEST therapy) for airway clearance (AC) in CF patients with mild to…
- Trial name
- EF/Vest (NCT02277626)
- Testing
- Electro Flo 5000, Incourage Vest System
- Volunteers
- 15 people
- Sponsor
- Stanford University
Asthma
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
Comparing one versus two doses of oral dexamethasone for the treatment of asthma in the pediatric emergency department.
- Trial name
- R2D2 (NCT02725008)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Geoffrey W Jara-Almonte
Cystic Fibrosis
Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients
The purpose of this actual use human factors (HF) study is to validate the approved US TOBI Podhaler Instructions for Use (IFU), by establishing that the IFU effectively communicates the information necessary to achieve safe and…
- Trial name
- NCT02178540
- Testing
- Tobi Podhaler
- Where
- 13 sites in United States
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Infant, Newborn, Infant, Small for Gestational Age
Hydrocortisone for BPD
The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life.
- Conditions
- Infant, Newborn, Infant, Small for Gestational Age, Infant, Very Low Birth Weight, Infant, Premature
- Trial name
- NCT01353313
- Testing
- Hydrocortisone
- Where
- 20 sites in United States
- Volunteers
- 800 people
- Sponsor
- NICHD Neonatal Research Network
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.